Exemestaz 25mg Tab

• Breast cancer
  
  

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Exemestaz 25mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.
Some common side effects include:

• Headache
  
• Dizziness
  
• Rash
  
• Nausea
  
• Increased sweating
  
• Fracture
  
• Vomiting
  
• Weakness
  
• Abdominal pain
  
• Osteoporosis
  
• Diarrhea
  
• Peripheral edema
  
• Insomnia (difficulty in sleeping)
  
• Decreased white blood cell count (lymphocytes)
  
• Low blood platelets
  
• Decreased appetite
  
• Depression
  
• Carpal tunnel syndrome
  
• Paresthesia (tingling or pricking sensation)
  
• Constipation
  
• Urticaria
  
• Hair loss
  
• Itching
• Increased appetite

Seek medical attention in case of any unusual or severe side effects immediately.

• Doctor determines the exact dose and duration with Exemestaz 25mg Tablet as per the overall health condition of the patient.
• This tablet should be taken with food or after food, but at the fix time every day to get effective results.
• Don't miss a dose or overdose on the medicine. Swallow it as a whole with a glass of water and do not crush, chew, or open it.
  

• Exemestaz 25mg Tablet is an anticancer medicine with Exemestane as an active ingredient.
• It belongs to the class of drug known as aromatase inhibitor.
• It works by blocking the action of enzyme responsible for the production of female hormone estrogen to lower its amount in the body.
• It results in controlling the growth of cancer cells as some breast cancer cells require estrogen to multiply
  

• Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., ... & Bliss, J. M. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350(11), 1081-1092 - https://pubmed.ncbi.nlm.nih.gov/15014181/
• Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., ... & Coombes, R. C. (2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. The lancet oncology, 8(2), 119-127 - https://pubmed.ncbi.nlm.nih.gov/17267326/
• Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., ... & Francis, P. A. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New England Journal of Medicine, 371(2), 107-118 - https://pubmed.ncbi.nlm.nih.gov/24881463/
• Deeks, E. D., & Scott, L. J. (2009). Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs, 69(7), 889-918 - https://pubmed.ncbi.nlm.nih.gov/19441873/
• Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., ... & Richardson, H. (2011). Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine, 364(25), 2381-2391 - https://pubmed.ncbi.nlm.nih.gov/21639806/​